Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week High – Here’s Why

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $25.11 and last traded at $25.11, with a volume of 5030 shares. The stock had previously closed at $24.44.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on the stock. TD Cowen began coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating for the company. Sanford C. Bernstein upped their price objective on Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Evercore set a $33.00 price objective on Dyne Therapeutics in a research note on Friday, May 15th. Wall Street Zen upgraded Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, July 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Dyne Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $34.17.

Dyne Therapeutics Trading Up 1.1%

The firm has a market cap of $4.83 billion, a PE ratio of -8.04 and a beta of 1.06. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17. The business has a fifty day moving average price of $20.76 and a 200 day moving average price of $18.72.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Monday, May 11th. The company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.04. During the same period in the previous year, the firm posted ($1.05) EPS. Analysts forecast that Dyne Therapeutics, Inc. will post -3.01 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Erick Lucera sold 2,362 shares of the business’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total transaction of $48,113.94. Following the completion of the sale, the chief financial officer owned 121,563 shares in the company, valued at approximately $2,476,238.31. The trade was a 1.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jason P. Rhodes sold 297,211 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $23.26, for a total transaction of $6,913,127.86. Following the completion of the transaction, the director owned 2,962 shares of the company’s stock, valued at approximately $68,896.12. The trade was a 99.01% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have purchased 9,000 shares of company stock valued at $156,800 and have sold 1,665,542 shares valued at $36,321,576. 9.46% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds have recently made changes to their positions in DYN. Hilton Head Capital Partners LLC acquired a new stake in shares of Dyne Therapeutics during the first quarter worth about $26,000. Strs Ohio acquired a new position in Dyne Therapeutics during the fourth quarter worth approximately $51,000. Aster Capital Management DIFC Ltd acquired a new position in Dyne Therapeutics during the fourth quarter worth approximately $84,000. Steward Partners Investment Advisory LLC lifted its stake in Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Dyne Therapeutics by 26.2% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock valued at $136,000 after buying an additional 1,440 shares during the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.